KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Inventory (2016 - 2025)

Pacira BioSciences has reported Inventory over the past 16 years, most recently at $152.9 million for Q4 2025.

  • Quarterly results put Inventory at $152.9 million for Q4 2025, up 22.02% from a year ago — trailing twelve months through Dec 2025 was $152.9 million (up 22.02% YoY), and the annual figure for FY2025 was $152.9 million, up 22.02%.
  • Inventory for Q4 2025 was $152.9 million at Pacira BioSciences, down from $157.7 million in the prior quarter.
  • Over the last five years, Inventory for PCRX hit a ceiling of $157.7 million in Q3 2025 and a floor of $64.6 million in Q1 2021.
  • Median Inventory over the past 5 years was $99.6 million (2021), compared with a mean of $105.4 million.
  • Biggest five-year swings in Inventory: skyrocketed 60.45% in 2022 and later dropped 10.31% in 2023.
  • Pacira BioSciences' Inventory stood at $98.6 million in 2021, then dropped by 2.52% to $96.1 million in 2022, then grew by 8.63% to $104.4 million in 2023, then rose by 20.06% to $125.3 million in 2024, then increased by 22.02% to $152.9 million in 2025.
  • The last three reported values for Inventory were $152.9 million (Q4 2025), $157.7 million (Q3 2025), and $148.2 million (Q2 2025) per Business Quant data.